Literature DB >> 2384307

5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study.

J T Guy1, T Fleming, T W Pollock, S E Rivkin, R P Pugh, H Saiers, H E Hynes, J F Boyd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2384307     DOI： 10.1007/bf00177261

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  3 in total

1.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

2.  A model for the action of vinblastine in vivo.

Authors:  F A Valeriote; W R Bruce; B E Meeker
Journal:  Biophys J       Date:  1966-03       Impact factor: 4.033

3.  Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer.

Authors:  H Y Yap; G R Blumenschein; M J Keating; G N Hortobagyi; C K Tashima; T L Loo
Journal:  Cancer Treat Rep       Date:  1980 Feb-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.